Tiziana Life Sciences Ltd., a biotechnology company focused on developing innovative immunomodulation therapies, has announced that its CEO, Ivor Elrifi, will present recent clinical findings related to its lead drug candidate, intranasal foralumab, at the Bio International Convention in Boston, Massachusetts. The presentation, titled "Treatment of Neuroinflammation with Intranasal Foralumab," is scheduled for June 18, 2025, at 11:45 AM ET. Intranasal foralumab is the first fully human anti-CD3 monoclonal antibody administered via the intranasal route, aiming to promote immune tolerance with minimal systemic immune suppression. Tiziana Life Sciences is currently conducting a Phase 2 trial for non-active Secondary Progressive Multiple Sclerosis and is planning to initiate a Phase 2 trial for early Alzheimer's Disease. The results of these trials will be discussed during the presentation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.